Because of its strong and consistent expression in HRS and ALCL cells and the limited expression in normal lymphoid tissues, the CD30 molecule was considered a suitable immunotherapeutic target [21, 35, 78]. The gene discussed is TNFRSF8; the disease is anaplastic large cell lymphoma.